{"id":2534,"date":"2020-09-28T16:02:41","date_gmt":"2020-09-28T21:02:41","guid":{"rendered":"http:\/\/nueva.idcbis.org.co\/?page_id=2534"},"modified":"2024-05-20T16:36:49","modified_gmt":"2024-05-20T21:36:49","slug":"investigacion","status":"publish","type":"page","link":"https:\/\/idcbis.org.co\/en\/investigacion\/","title":{"rendered":"Investigacio\u0301n"},"content":{"rendered":"

<\/div><\/div>
<\/div>
\"Logo<\/div><\/div>
<\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
<\/div>
<\/p>\n

The IDCBIS formed the Transfusion, Tissue and Cellular Medicine Research Group (GIMTTyC).<\/span><\/h1>\n

\n<\/div>

<\/div><\/div><\/div><\/div><\/div>
<\/p>\n

IDCBIS conducts population health research in the following areas:<\/h3>\n
    \n
  1. Research and development in Advanced Therapies (cell therapy, gene therapy) and their clinical application. \u00bb<\/span> more information<\/b><\/a><\/li>\n
  2. Research and development of biotechnological products and services in tissue engineering, tissue and regenerative medicine. \u00bb<\/span> more information<\/b><\/a><\/li>\n
  3. Hematopoietic Progenitor Cell Research, Clinical Application and CPH Donor Registry \u00bb<\/span> more information<\/b><\/a><\/li>\n
  4. Research and development of biotechnological products and services in transfusion medicine and advanced immunohematology. \u00bb<\/span> more information<\/b><\/a><\/li>\n
  5. Research for the Social Appropriation of Science and Scientific Culture<\/li>\n
  6. Research for organizational strengthening, innovation and competitiveness of IDCBIS as an actor of the National Science, Technology and Innovation System.<\/li>\n<\/ol>\n

    \n<\/div><\/div><\/div>

    \"Mujer<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
    <\/div><\/div><\/div><\/div><\/div>
    • Research and development in Advanced Therapies (cell therapy, gene therapy) and their clinical application.<\/span><\/li>
    • Research and development of biotechnological products and services in tissue engineering, tissue and regenerative medicine.<\/span><\/li>
    • L\u00ednea de investigaci\u00f3n Banco de Sangre de Cord\u00f3n Umbilical y Trasplante de C\u00e9lulas de Progenitoras Hematopoy\u00e9ticas<\/span><\/li>
    • Research and development of biotechnological products and services in transfusion medicine and advanced immunohematology.<\/span><\/li><\/ul>
      \r\n\t\t\t
      Research and development in Advanced Therapies (cell therapy, gene therapy) and their clinical application.<\/span><\/div>\r\n\t\t\t
      <\/p>\n

      A trav\u00e9s de la Unidad de Terapias Avanzadas se promueve la generaci\u00f3n de conocimiento e innovaci\u00f3n en ciencias biom\u00e9dicas mediante la articulaci\u00f3n de actores en ciencia y tecnolog\u00eda, consolidando un equipo de investigadores altamente capacitados.<\/h3>\n

      \"\"<\/p>\n

      Projects under development<\/span><\/h2>\n

      Grupo de Innovaci\u00f3n y Producci\u00f3n de Terapias Avanzadas<\/strong><\/span><\/h3>\n
        \n
      • \n

        Escalamiento de productos de terapia avanzada<\/h3>\n<\/li>\n
      • \n

        Modelos precl\u00ednicos para terapia avanzada<\/h3>\n<\/li>\n
      • \n

        Generation of spheroids for immunomodulation studies.<\/h3>\n<\/li>\n
      • \n

        Ves\u00edculas extracelulares para aplicaciones biotecnol\u00f3gicas<\/h3>\n<\/li>\n
      • \n

        Ves\u00edculas extracelulares y su biog\u00e9nesis<\/h3>\n<\/li>\n
      • \n

        Apoptotic bodies and immunomodulation<\/h3>\n<\/li>\n<\/ul>\n

        Grupo de Terapias Adoptativas y Avanzadas<\/strong><\/span><\/h3>\n
          \n
        • \n

          Terapia Adoptiva Antiviral<\/h3>\n<\/li>\n
        • \n

          Terapia de Linfocitos Infiltrantes de Tumor<\/h3>\n<\/li>\n
        • \n

          Dise\u00f1o de dispositivos para expansi\u00f3n de linfocitos T<\/h3>\n<\/li>\n<\/ul>\n

          Grupo de Ingenier\u00eda Tisular<\/strong><\/span><\/h3>\n
            \n
          • \n

            Estudios de comparabilidad de dermis acelulares<\/h3>\n<\/li>\n
          • \n

            Estudio de compatibilidad y eficacia de dermis acelular<\/h3>\n<\/li>\n
          • \n

            Bioingenier\u00eda del tejido cut\u00e1neo<\/h3>\n<\/li>\n
          • \n

            Dermis acelular re-celularizada para regeneraci\u00f3n cut\u00e1nea<\/h3>\n<\/li>\n
          • \n

            Design, modeling and 3D printing of skeletal structures<\/h3>\n<\/li>\n
          • \n

            Bioingenier\u00eda del tejido \u00f3seo<\/h3>\n<\/li>\n
          • \n

            Encapsulaci\u00f3n de MSC para terapia avanzada<\/h3>\n<\/li>\n
          • \n

            Generaci\u00f3n de modelos 3D de hematopoyesis<\/h3>\n<\/li>\n
          • \n

            Sistemas de liberaci\u00f3n prolongada de antibi\u00f3ticos para ingenier\u00eda tisular<\/h3>\n<\/li>\n
          • \n

            Design of instruments and technologies for biomedical investigation.<\/h3>\n<\/li>\n
          • \n

            Sistemas de liberaci\u00f3n prolongada de factores para ingenier\u00eda tisular<\/h3>\n<\/li>\n
          • \n

            Andamios de regeneraci\u00f3n cut\u00e1nea con nuevos biomateriales<\/h3>\n<\/li>\n<\/ul>\n

            Grupo de Ingenier\u00eda Molecular y Celular<\/strong><\/span><\/h3>\n
              \n
            • \n

              CAR-T cell engineering<\/h3>\n<\/li>\n
            • \n

              Terapias avanzada para SARS-CoV2<\/h3>\n<\/li>\n
            • \n

              Effector capacity developed by \"CAR T-cells\" in the expansion process.<\/h3>\n<\/li>\n
            • \n

              Ves\u00edculas extracelulares y mecanismos de acci\u00f3n<\/h3>\n<\/li>\n
            • \n

              Inmunoterapias mejorada basadas en ingenier\u00eda gen\u00e9tica de MSC<\/h3>\n<\/li>\n
            • \n

              Ingenier\u00eda de ves\u00edculas extracelulares como veh\u00edculos de transferencia g\u00e9nica<\/h3>\n<\/li>\n
            • \n

              CRISPR-Cas9-based disease models<\/h3>\n<\/li>\n<\/ul>\n

              A trav\u00e9s de la Unidad de Terapias Avanzadas se promueve la generaci\u00f3n de conocimiento e innovaci\u00f3n en ciencias biom\u00e9dicas mediante la articulaci\u00f3n de actores en ciencia y tecnolog\u00eda, consolidando un equipo de investigadores altamente capacitados.<\/h3>\n

              \n<\/div>\r\n\t\t<\/div>

              \r\n\t\t\t
              Research and development of biotechnological products and services in tissue engineering, tissue and regenerative medicine.<\/span><\/div>\r\n\t\t\t
              <\/div>\r\n\t\t<\/div>
              \r\n\t\t\t
              L\u00ednea de investigaci\u00f3n Banco de Sangre de Cord\u00f3n Umbilical y Trasplante de C\u00e9lulas de Progenitoras Hematopoy\u00e9ticas<\/span><\/div>\r\n\t\t\t
              <\/p>\n

              La l\u00ednea de investigaci\u00f3n que desarrolla el Banco de Sangre de Cord\u00f3n Umbilical- BSCU dentro del grupo de investigaci\u00f3n del Instituto GIMMTyC denominada \u201cBanco de sangre de cord\u00f3n umbilical y trasplante de progenitores Hematopoy\u00e9ticos\u201d constituido por investigadores en ciencias biol\u00f3gicas y biom\u00e9dicas, tiene como misi\u00f3n realizar actividades de investigaci\u00f3n, desarrollo e innovaci\u00f3n en productos derivados de la sangre de cord\u00f3n umbilical y otras fuentes de progenitores hematopoy\u00e9ticos con el objeto de establecer los factores biol\u00f3gicos, moleculares y psicosociales determinantes en el trasplante de progenitores hematopoy\u00e9ticos.<\/h3>\n

              Los investigadores trabajan en actividades de investigaci\u00f3n y desarrollo que han permitido el avance de los procesos de colecta, selecci\u00f3n, criopreservaci\u00f3n, registro, b\u00fasquedas, reserva, distribuci\u00f3n y trasplante bajo un sistema de gesti\u00f3n de calidad y en coordinaci\u00f3n con \u00e1reas como Microbiolog\u00eda y Control de Calidad de la Sangre del IDCBIS para cumplir con los siguientes objetivos:<\/h3>\n
                \n
              • \n

                Optimizar e implementar procesos de banqueo y registro de unidades de sangre de cord\u00f3n umbilical para trasplante.<\/span><\/h3>\n<\/li>\n
              • \n

                Investigar en los determinantes de \u00e9xito del trasplante de progenitores hematopoy\u00e9ticos, con un enfoque en fortalecer procesos de manufacturaci\u00f3n, desarrollo de biomarcadores y escalamiento a ensayos cl\u00ednicos.<\/span><\/h3>\n<\/li>\n
              • \n

                Desarrollar investigaciones en productos derivados de la sangre de cord\u00f3n umbilical y otras fuentes de progenitores hematopoy\u00e9ticos con potencial terap\u00e9utico para diferentes patolog\u00edas y desarrollar estrategias de colaboraci\u00f3n para su escalamiento cl\u00ednico.<\/span><\/h3>\n<\/li>\n
              • \n

                Articular las investigaciones b\u00e1sicas y aplicadas del modelo biol\u00f3gico con los modelos psicosocial y cl\u00ednico para mejorar el trasplante de progenitores hematopoy\u00e9ticos.<\/span><\/h3>\n<\/li>\n<\/ul>\n

                <\/h3>\n

                Registro Nacional de Donantes de C\u00e9lulas Progenitoras Hematopoy\u00e9ticas<\/h3>\n

                El RNDCPH corresponde al proyecto de investigaci\u00f3n \u201cEstudios t\u00e9cnicos para el establecimiento y organizaci\u00f3n de un Registro Nacional de Donantes de C\u00e9lulas Progenitoras Hematopoy\u00e9ticas en Colombia\u201d.<\/h3>\n

                BPIN2015000100054 cuyo objetivo principal es dise\u00f1ar el modelo organizativo, log\u00edstico y de infraestructura requerido para implementar un registro nacional de donantes en Colombia.<\/h3>\n

                Este proyecto cuenta con 8 objetivos espec\u00edficos, as\u00ed:<\/h3>\n
                  \n
                1. \n

                  Dise\u00f1ar una estrategia para generar cultura de donaci\u00f3n de c\u00e9lulas progenitoras hematopoy\u00e9ticas en Colombia.<\/h3>\n<\/li>\n
                2. \n

                  Determinar la plataforma computacional adecuada para satisfacer las necesidades de un registro nacional de donantes de c\u00e9lulas progenitoras hematopoy\u00e9ticas en Colombia.<\/h3>\n<\/li>\n
                3. \n

                  Incrementar la informaci\u00f3n cient\u00edfica y el talento humano capacitado en la organizaci\u00f3n y operaci\u00f3n de un sistema nacional de donaci\u00f3n de c\u00e9lulas progenitoras hematopoy\u00e9ticas.<\/h3>\n<\/li>\n
                4. \n

                  Consolidar informaci\u00f3n y generar estad\u00edsticas sobre oferta y demanda de trasplante alog\u00e9nico no relacionado en Colombia.<\/h3>\n<\/li>\n
                5. \n

                  Generar propuestas de normativa y lineamientos t\u00e9cnicos en conjunto con el Instituto Nacional de Salud, para la organizaci\u00f3n y operaci\u00f3n de un sistema de donaci\u00f3n y trasplante alog\u00e9nico de progenitores hematopoy\u00e9ticos.<\/h3>\n<\/li>\n
                6. \n

                  Proponer una estructura administrativa y financiera para la implementaci\u00f3n y operaci\u00f3n de un registro nacional de donantes de c\u00e9lulas progenitoras hematopoy\u00e9ticas en Colombia.<\/h3>\n<\/li>\n
                7. \n

                  Promover la participaci\u00f3n del sector p\u00fablico en el trasplante alog\u00e9nico no relacionado en Colombia.<\/h3>\n<\/li>\n
                8. \n

                  Generar informaci\u00f3n para implementar y operar centros de captaci\u00f3n de donantes y de recolecci\u00f3n de c\u00e9lulas progenitoras hematopoy\u00e9ticas en Colombia.<\/h3>\n<\/li>\n<\/ol>\n

                  \"\"<\/p>\n

                  \n<\/div>\r\n\t\t<\/div>

                  \r\n\t\t\t
                  Research and development of biotechnological products and services in transfusion medicine and advanced immunohematology.<\/span><\/div>\r\n\t\t\t
                  <\/p>\n

                  Se ha avanzado en la implementaci\u00f3n de nuevos servicios de Inmunohematolog\u00eda avanzada.<\/strong><\/span><\/h3>\n
                    \n
                  • \n

                    Standardization of the method of cryopreservation of red blood cell units with rare phenotypes.<\/span><\/h3>\n<\/li>\n
                  • \n

                    Validaci\u00f3n de t\u00e9cnicas de genotipado eritrocitario Ag RH y RHCE.<\/span><\/h3>\n<\/li>\n
                  • \n

                    Incorporaci\u00f3n de infraestructura tecnol\u00f3gica para t\u00e9cnicas inmunohematol\u00f3gicas.<\/span><\/h3>\n<\/li>\n
                  • \n

                    Creaci\u00f3n de una genoteca de donantes de plaquetaf\u00e9resis<\/span><\/h3>\n<\/li>\n<\/ul>\n

                    In 2020, IDCBIS put into operation the first Molecular Immunohematology Laboratory in Colombia, creating in turn the Registry of Donors with Rare Blood Phenotypes, the first program of its kind in Colombia that will aim to identify people with unique or rare blood groups (i.e. not represented in phenotypes A, B, O, AB or in the RH system), to create a community of people who can be contacted at the national level at the time a blood donation with these characteristics is required.<\/h3>\n

                    The program, called IDCBIS Single Donor Registry, will help preserve the lives of that 0.01% of the population that has uncommon blood groups; and therefore, in case they require a transfusion, they are at risk of receiving blood that is not completely compatible and that their immune system could reject by identifying it as a foreign element.<\/h3>\n

                    \n<\/div>\r\n\t\t<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>

                    <\/div><\/div>
                    <\/p>\n

                    CATEGORY GROUP A1 BY COLCIENCIAS<\/span><\/h3>\n

                    COL-0133477<\/span><\/h4>\n

                    \n<\/div>

                    <\/div>
                    <\/p>\n

                    Actualmente tiene m\u00e1s de 50 proyectos
                    \nde investigaci\u00f3n<\/span> en curso<\/h3>\n

                    \n<\/div><\/div><\/div>

                    <\/div><\/div><\/div><\/div>
                    <\/div>
                    <\/p>\n

                    1. Terapias avanzadas, celular, g\u00e9nica e ingenier\u00eda de tejidos<\/span><\/h3>\n

                    \n<\/div>

                    <\/div><\/div><\/div>
                    <\/p>\n

                    2. Banco de sangre de cord\u00f3n umbilical y trasplante de progenitores hematopoy\u00e9ticos<\/span><\/h3>\n

                    \n<\/div><\/div><\/div>

                    <\/p>\n

                    3. Banco de sangre y medicina transfusional<\/span><\/h3>\n

                    \n<\/div><\/div><\/div>

                    <\/p>\n

                    4. Banco de tejidos humanos, terapia tisular y su aplicacion cl\u00ednica<\/span><\/h3>\n

                    \n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>

                    <\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
                    <\/div><\/div><\/div><\/div><\/div>
                    <\/div>
                    <\/p>\n

                    Strengthening in relation to I+D+I Environment \/ Investigation Center<\/span><\/h3>\n

                    \n<\/div>

                    <\/div>
                    <\/p>\n
                    MinCiencias under resolution 1763 of 2021 recognized IDCBIS as a Investigation Center, an actor of the national system of Science, Technology and Innovation.<\/h5>\n

                    \n<\/div>

                    <\/div><\/div><\/div>
                    <\/div>
                    <\/p>\n

                    Tax benefits<\/span><\/h3>\n

                    \n<\/div>

                    <\/div>
                    <\/p>\n

                    MinCiencias recognized the project \"Implementation of the BSCU and a cell therapy unit Hemocentro Distrital, SDS, Bogot\u00e1\". BPIN 20120001000186 for VAT exemption.<\/h4>\n

                    \n<\/div>

                    <\/div><\/div><\/div><\/div><\/div>
                    <\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
                    \"Gr\u00e1fica<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
                    <\/p>\n

                    Advanced therapies manufacturing area
                    \n(GMP Clean Room)<\/span><\/h2>\n

                    \n<\/div><\/div><\/div>

                    <\/p>\n

                    In 2020 the IDCBIS completed the installation of a laboratory called Clean Area, due to its maximum environmental control conditions (temperature, humidity, air pressure and contamination), being the only one in Colombia of this large size (280 m\u00b2 approximately) and degree of complexity. These state-of-the-art facilities put the Institute in a position to strengthen national and international scientific cooperation agreements and position it as a regional leader in innovation in cell therapy, gene therapy and tissue engineering.<\/span><\/h3>\n

                    \n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>

                    <\/div>
                    <\/div>
                    <\/div><\/div><\/div>
                    <\/div>
                    <\/div><\/div><\/div>
                    <\/div>
                    <\/div><\/div><\/div>
                    <\/div>
                    <\/div><\/div><\/div>
                    <\/div>
                    <\/div><\/div><\/div>
                    <\/div>
                    <\/div><\/div><\/div>
                    <\/div>
                    <\/div><\/div><\/div>
                    <\/div>
                    <\/div><\/div><\/div>
                    <\/div>
                    <\/div><\/div><\/div>
                    <\/div>
                    <\/div><\/div><\/div>
                    <\/div>
                    <\/div><\/div><\/div>
                    <\/div>
                    <\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>
                    <\/p>\n

                    Research projects on topics of institutional interest and impact on collective health.<\/span><\/h2>\n

                    \n<\/div>

                    <\/p>\n

                    3 Projects in execution SGR CTeI Allocation<\/span><\/h3>\n

                    \n<\/div>

                    <\/p>\n

                    Implementation of a public umbilical cord stem cell bank and a cell therapy unit District Hemocenter, Secretary of Health, Bogota.<\/h3>\n

                    BPIN 2012000100186<\/span><\/h3>\n

                    \n<\/div><\/div><\/div>

                    <\/p>\n

                    Technical studies for the establishment and organization of a national registry of hematopoietic progenitor cell donors in Colombia.<\/h3>\n

                    BPIN 2015000100054<\/span><\/h3>\n

                    \n<\/div><\/div><\/div>

                    <\/p>\n

                    Research oriented to the implementation of good practices for the clinical application of cellular therapies TPH model in Bogota.<\/h3>\n

                    BPIN 2016000100035<\/span><\/h3>\n

                    \n<\/div><\/div><\/div><\/div><\/div><\/div>

                    <\/p>\n

                    5 Projects Financed by Minciencias Calls for Proposals<\/span><\/h3>\n

                    \n<\/div>

                    <\/p>\n

                    \"Characterization of the immunoregulatory function of umbilical cord mesenchymal stromal cells as potential therapeutic tools in inflammation and allogenicity.\"<\/h3>\n

                    Contract No. 607-2018<\/span><\/h3>\n

                    \n<\/div><\/div><\/div>

                    <\/p>\n

                    \"Evaluation of the supporting capacity of mesenchymal stem cells from different tissues in the expansion of cord blood hematopoietic progenitor cells.\"<\/h3>\n

                    Contract No. 738-2018<\/span><\/h3>\n

                    \n<\/div><\/div><\/div>

                    <\/p>\n

                    \"Design and evaluation of skin substitutes generated from biological scaffolds and Wharton's jelly mesenchymal stromal stromal cells for chronic skin ulcer repair.\"<\/h3>\n

                    Contract No. 739-2018<\/span><\/h3>\n

                    \n<\/div><\/div><\/div><\/div>

                    <\/p>\n

                    \"Optimization of autologous dendritic cells as a strategy in immunotherapy in cancer patients\";<\/h3>\n

                    Contract No. 840-2018<\/span><\/h3>\n

                    \n<\/div><\/div><\/div>

                    <\/p>\n

                    Evaluation of Immunological Biomarkers in Ovarian Cancer Patients and their Potential Application in the Development of Cellular Therapies.<\/h3>\n

                    Contract No. 101-2021<\/span><\/h3>\n

                    \n<\/div><\/div><\/div>

                    <\/div><\/div><\/div><\/div><\/div><\/div>
                    <\/p>\n

                    3 Proyectos en ejecuci\u00f3n SGR – OCAD Centro Oriente<\/span><\/h3>\n

                    \n<\/div>

                    <\/p>\n

                    Desarrollo de un programa de producci\u00f3n biofarmac\u00e9utica y medicina personalizada para el tratamiento de enfermedades cr\u00f3nicas y degenerativas de alto impacto en salud p\u00fablica en Bogot\u00e1 Regi\u00f3n, Bogot\u00e1<\/h3>\n

                    BPIN 2021000050015<\/span><\/h3>\n

                    \n<\/div><\/div><\/div>

                    <\/p>\n

                    Desarrollo de productos de terapia t\u00edsular basados en aloinjertos frescos para el tratamiento de pacientes con patolog\u00edas osteocondrales en Bogot\u00e1 – Regi\u00f3n, Bogot\u00e1.<\/h3>\n

                    BPIN 2021000050016<\/span><\/h3>\n

                    \n<\/div><\/div><\/div>

                    <\/p>\n

                    Implementaci\u00f3n de una estrategia de apropiaci\u00f3n social del conocimiento para la construcci\u00f3n de una cultura cient\u00edfica en salud orientada a la promoci\u00f3n de h\u00e1bitos de vida saludables en Bogot\u00e1 – Regi\u00f3n Bogot\u00e1.<\/h3>\n

                    BPIN 2021000050017<\/span><\/h3>\n

                    \n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section>

                    \"Banner<\/div><\/div><\/div><\/div>
                    <\/p>\n

                    See all investigation articles<\/span><\/h3>\n

                    of IDCBIS in indexed journals<\/span><\/h3>\n

                    \n<\/div>CLICK HERE<\/span><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/section><\/p>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/idcbis.org.co\/en\/wp-json\/wp\/v2\/pages\/2534"}],"collection":[{"href":"https:\/\/idcbis.org.co\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idcbis.org.co\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idcbis.org.co\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idcbis.org.co\/en\/wp-json\/wp\/v2\/comments?post=2534"}],"version-history":[{"count":159,"href":"https:\/\/idcbis.org.co\/en\/wp-json\/wp\/v2\/pages\/2534\/revisions"}],"predecessor-version":[{"id":6022,"href":"https:\/\/idcbis.org.co\/en\/wp-json\/wp\/v2\/pages\/2534\/revisions\/6022"}],"wp:attachment":[{"href":"https:\/\/idcbis.org.co\/en\/wp-json\/wp\/v2\/media?parent=2534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}